Announced

Meridian Bioscience acquired the business of GenePOC from Debiopharm for up to $120m.

Synopsis

Meridian Bioscience, a provider of diagnostic testing solutions and life science raw materials, acquired the business of GenePOC, a Quebec, Canada-based provider of molecular diagnostic instruments and assays, from Debiopharm for up to $120m. Jack Kenny, Chief Executive Officer, commented: “This is a critical element of our strategy to re-position our Diagnostics business for sustainable long-term growth. GenePOC’s revogeneTM platform is an excellent fit for our customers and strategy to offer gastrointestinal-focused and other targeted diagnostic solutions to meet the diverse needs of today’s more complex health care system. We welcome the GenePOC team to the Meridian family and look forward to leveraging Meridian’s strong and established commercial infrastructure to offer revogeneTM and its menu of assays to our current and new customers.”

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US